Last Price
0.12
Today's Change
-0.001 (0.83%)
Day's Change
0.115 - 0.122
Trading Volume
690,900
Profile
CNSP
Exchange: NASDAQ Capital Market NASDAQ Capital Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Mr. John Michael Climaco Esq., J.D. Mr. John Michael Climaco Esq., J.D.
Full Time Employees: 3 3
IPO Date: 2019-11-08 2019-11-08
CIK: 0001729427 0001729427
ISIN: US18978H2013 US18978H2013
CUSIP: 18978H102 18978H102
Beta: 1.05 1.05
Last Dividend: 0.00 0.00
Dcf Diff: -2.16 -2.16
Dcf: 3.29 3.29
Description
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Address
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Featured Posts
12
Latest Videos
Apps
Top Articles
1
CEO Morning Brief
OpenAI Lets Anyone Use Its New Voice Assistant in Third-party Apps
2
CEO Morning Brief
3
4
CEO Morning Brief
5
CEO Morning Brief
Bitcoin Totters in Poor Start to Token’s Best Month Historically
#
Stock
Score
Daily Stocks
Stock
Last
Change
Volume
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
